Drug Trial Radar · NCT05718921
A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jan 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
54
Actual
Start
Apr 8, 2023
Primary completion
Aug 14, 2023
Study completion Dec 14, 2023
Sponsor
- Lead sponsor
- Hangzhou Yirui Pharmaceutical Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in healthy adult subjects.
Conditions
- Atopic Dermatitis
- Psoriasis
Interventions
YR001 Dose A on low body surface areaDrug
Part A: Single topical dose
YR001 Dose A on middle body surface areaDrug
Part A: Single topical dose
YR001 Dose A on high body surface areaDrug
Part A: Single topical dose
YR001 Dose B on low body surface areaDrug
Part A: Single topical dose
YR001 Dose B on middle body surface areaDrug
Part A: Single topical dose
YR001 Dose B on high body surface areaDrug
Part A: Single topical dose
Placebo on low body surface areaDrug
Part A: Single topical dose
Placebo on middle body surface areaDrug
Part A: Single topical dose
Placebo on high body surface areaDrug
Part A: Single topical dose
YR001 Dose A on high body surface area twice dailyDrug
Part B: Multiple topical dose
YR001 Dose B on high body surface area twice dailyDrug
Part B: Multiple topical dose
Placebo on high body surface area twice dailyDrug
Part B: Multiple topical dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Safety and Maximum Tolerate Dose (MTD)Time frame: day 0 to day 8
- Part B: Safety and Maximum Tolerate Dose (MTD)Time frame: day 0 to day 22
Locations
1 site in 1 country. Site status is shown where the registry gives one.
California Dermatology & Clinical Research Institute
Encinitas, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.